Skip to content
The People's CodeSearch
Menu

Changes to the Code

S. 545 · Combating Illicit Xylazine Act ·

Reported by committee · step 2 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

21 U.S.C. § 802 Definitions

+29 −1Shown
More for 21 U.S.C. § 802
Read § 802Only this section
2 changes the bill asks for here, 2 carried out
  1. Carried out:

    Section 102 of the Controlled Substances Act (21 U.S.C. 802) is amended by adding at the end the following:(61) The term “xylazine” means the substance xylazine, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible..

  2. Carried out:

    Section 102 of the Controlled Substances Act (21 U.S.C. 802) is amended by striking paragraph (27) and inserting the following:(27) (A) Except as provided in subparagraph (B), the term “ultimate user” means a person who has lawfully obtained, and who possesses, a controlled substance for the use by the person or for the use of a member of the household of the person or for an animal owned by the person …

§ 802(26)–(29)

Start of § 802 to (25)(C) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(26)(26) (26)
The term “State” means a State of the United States, the District of Columbia, and any commonwealth, territory, or possession of the United States.The term “State” means a State of the United States, the District of Columbia, and any commonwealth, territory, or possession of the United States.
(27)(27) (27)
(27)(A)(A) [inserted: ]
[inserted: Except as provided in subparagraph (B), the term “ultimate user” means a person who has lawfully obtained, and who possesses, a controlled substance for the use by the person or for the use of a member of the household of the person or for an animal owned by the person or by a member of the household of the person.]
(27)(B)(B) [inserted: ]
(27)(B)(i)(i) [inserted: ]
[inserted: In the case of xylazine, other than for a drug product approved under subsection (b) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355), the term “ultimate user” means a person—]
(27)(B)(i)(I)(I) [inserted: ]
[inserted: to whom xylazine was dispensed by—]
(27)(B)(i)(I)(aa)(aa) [inserted: ]
[inserted: a veterinarian registered under this Act; or]
(27)(B)(i)(I)(bb)(bb) [inserted: ]
[inserted: a pharmacy registered under this Act pursuant to a prescription of a veterinarian registered under this Act; and]
(27)(B)(i)(II)(II) [inserted: ]
[inserted: who possesses xylazine for—]
(27)(B)(i)(II)(aa)(aa) [inserted: ]
[inserted: an animal owned by the person or by a member of the household of the person;]
(27)(B)(i)(II)(bb)(bb) [inserted: ]
[inserted: an animal under the care of the person;]
(27)(B)(i)(II)(cc)(cc) [inserted: ]
[inserted: use in government animal-control programs authorized under applicable Federal, State, Tribal, or local law; or]
(27)(B)(i)(II)(dd)(dd) [inserted: ]
[inserted: use in wildlife programs authorized under applicable Federal, State, Tribal, or local law.]
(27)(B)(ii)(ii) [inserted: ]
[inserted: In this subparagraph, the term “person” includes—]
(27)(B)(ii)(I)(I) [inserted: ]
[inserted: a government agency or business where animals are located; and]
(27)(B)(ii)(II)(II) [inserted: ]
[inserted: an employee or agent of an agency or business acting within the scope of their employment or agency.]
(27)[struck: The term “ultimate user” means a person who has lawfully obtained, and who possesses, a controlled substance for his own use or for the use of a member of his household or for an animal owned by him or by a member of his household.]
(28)(28) (28)
The term “United States”, when used in a geographic sense, means all places and waters, continental or insular, subject to the jurisdiction of the United States.The term “United States”, when used in a geographic sense, means all places and waters, continental or insular, subject to the jurisdiction of the United States.
(29)(29) (29)
The term “maintenance treatment” means the dispensing, for a period in excess of twenty-one days, of a narcotic drug in the treatment of an individual for dependence upon heroin or other morphine-like drugs.The term “maintenance treatment” means the dispensing, for a period in excess of twenty-one days, of a narcotic drug in the treatment of an individual for dependence upon heroin or other morphine-like drugs.

§ 802(59)–(61)

(30)–(59) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(59)(B)(B) (B)
any offense that would be a felony violation of section 113 of title 18, if the offense were committed in the special maritime and territorial jurisdiction of the United States, for which the offender served a term of imprisonment of more than 12 months.any offense that would be a felony violation of section 113 of title 18, if the offense were committed in the special maritime and territorial jurisdiction of the United States, for which the offender served a term of imprisonment of more than 12 months.
(60)(60) (60)
The term “fentanyl-related substance” has the meaning given the term in subsection (e)(2) of schedule I of section 812(c) of this title.The term “fentanyl-related substance” has the meaning given the term in subsection (e)(2) of schedule I of section 812(c) of this title.
(61)(61) [inserted: ]
[inserted: The term “xylazine” means the substance xylazine, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible.]

21 U.S.C. § 827 Records and reports of registrants

+2 −22 of 4 shown
More for 21 U.S.C. § 827
Read § 827Only this section
4 changes the bill asks for here, 2 carried out
  1. Carried out:

    by inserting or xylazine after gamma hydroxybutyric acid;

  2. Not carried out:

    by inserting or 512 after section 505; and

    “section 505” isn't in § 827(i) in the Code as we have it. The law may have changed since the bill was drafted.

    Technical detail“section 505” not found in /us/usc/t21/s827/i
  3. Not carried out:

    by inserting respectively, after the Federal Food, Drug, and Cosmetic Act,; and

    “the Federal Food, Drug, and Cosmetic Act,” isn't in § 827(i) in the Code as we have it. The law may have changed since the bill was drafted.

    Technical detail“the Federal Food, Drug, and Cosmetic Act,” not found in /us/usc/t21/s827/i
  4. Carried out:

    in paragraph (6), by inserting and xylazine after gamma hydroxybutyric acid.

§ 827(h)–(i)

Start of § 827 to (g) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(h)(h) Change of address(h) Change of address
Every registrant under this subchapter shall be required to report any change of professional or business address in such manner as the Attorney General shall by regulation require.Every registrant under this subchapter shall be required to report any change of professional or business address in such manner as the Attorney General shall by regulation require.
(i)(i) Reporting requirements for GHB(i) Reporting requirements for GHB
In the case of a drug product containing gamma hydroxybutyric acid for which an application has been approved under section 355 of this title, the Attorney General may, in addition to any other requirements that apply under this section with respect to such a drug product, establish any of the following as reporting requirements:In the case of a drug product containing gamma hydroxybutyric acid [inserted: or xylazine ]for which an application has been approved under section 355 of this title, the Attorney General may, in addition to any other requirements that apply under this section with respect to such a drug product, establish any of the following as reporting requirements:
(i)(1)(1) (1)
That every person who is registered as a manufacturer of bulk or dosage form, as a packager, repackager, labeler, relabeler, or distributor shall report acquisition and distribution transactions quarterly, not later than the 15th day of the month succeeding the quarter for which the report is submitted, and annually report end-of-year inventories.That every person who is registered as a manufacturer of bulk or dosage form, as a packager, repackager, labeler, relabeler, or distributor shall report acquisition and distribution transactions quarterly, not later than the 15th day of the month succeeding the quarter for which the report is submitted, and annually report end-of-year inventories.
(i)(2)(2) (2)
That all annual inventory reports shall be filed no later than January 15 of the year following that for which the report is submitted and include data on the stocks of the drug product, drug substance, bulk drug, and dosage forms on hand as of the close of business December 31, indicating whether materials reported are in storage or in process of manufacturing.That all annual inventory reports shall be filed no later than January 15 of the year following that for which the report is submitted and include data on the stocks of the drug product, drug substance, bulk drug, and dosage forms on hand as of the close of business December 31, indicating whether materials reported are in storage or in process of manufacturing.

§ 827(i)–(j)

(i)(3)–(4) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(i)(5)(5) (5)
That each dispensing practitioner shall maintain for each prescription the name of the prescribing practitioner, the prescribing practitioner’s Federal and State registration numbers, with the expiration dates of these registrations, verification that the prescribing practitioner possesses the appropriate registration to prescribe this controlled substance, the patient’s name and address, the name of the patient’s insurance provider and documentation by a medical practitioner licensed and registered to prescribe the drug of the patient’s medical need for the drug. Such information shall be available for inspection and copying by the Attorney General.That each dispensing practitioner shall maintain for each prescription the name of the prescribing practitioner, the prescribing practitioner’s Federal and State registration numbers, with the expiration dates of these registrations, verification that the prescribing practitioner possesses the appropriate registration to prescribe this controlled substance, the patient’s name and address, the name of the patient’s insurance provider and documentation by a medical practitioner licensed and registered to prescribe the drug of the patient’s medical need for the drug. Such information shall be available for inspection and copying by the Attorney General.
(i)(6)(6) (6)
That section 830(b)(3) of this title (relating to mail order reporting) applies with respect to gamma hydroxybutyric acid to the same extent and in the same manner as such section applies with respect to the chemicals and drug products specified in subparagraph (A)(i) of such section.That section 830(b)(3) of this title (relating to mail order reporting) applies with respect to gamma hydroxybutyric acid [inserted: and xylazine ]to the same extent and in the same manner as such section applies with respect to the chemicals and drug products specified in subparagraph (A)(i) of such section.
(j)(j) Electronic reporting format(j) Electronic reporting format
All of the reports required under this section shall be provided in an electronic format.All of the reports required under this section shall be provided in an electronic format.

Step through the changes